Pictet Asset Management Holding SA Raises Stake in Roivant Sciences Ltd. $ROIV

Pictet Asset Management Holding SA lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 790.3% during the fourth quarter, HoldingsChannel reports. The firm owned 2,312,436 shares of the company’s stock after purchasing an additional 2,052,693 shares during the period. Pictet Asset Management Holding SA’s holdings in Roivant Sciences were worth $50,180,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. UBS Group AG boosted its position in Roivant Sciences by 570.0% in the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Roivant Sciences by 11,507.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock worth $150,535,000 after acquiring an additional 6,877,348 shares during the period. Perceptive Advisors LLC bought a new stake in shares of Roivant Sciences during the second quarter valued at approximately $37,546,000. Vanguard Group Inc. raised its stake in shares of Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after acquiring an additional 3,254,113 shares in the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Roivant Sciences by 316.5% in the third quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock valued at $60,187,000 after purchasing an additional 3,022,851 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Sanford C. Bernstein began coverage on Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective on the stock. Guggenheim lifted their target price on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Piper Sandler increased their price target on Roivant Sciences from $22.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 16th. Weiss Ratings lowered Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, February 9th. Finally, TD Cowen restated a “buy” rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $30.55.

Insider Buying and Selling at Roivant Sciences

In other news, CEO Matthew Gline sold 289,774 shares of Roivant Sciences stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $29.16, for a total value of $8,449,809.84. Following the transaction, the chief executive officer directly owned 16,736,116 shares in the company, valued at approximately $488,025,142.56. This trade represents a 1.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Jennifer Humes sold 13,538 shares of the business’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the transaction, the chief accounting officer directly owned 84,191 shares of the company’s stock, valued at approximately $2,388,498.67. The trade was a 13.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 5,085,398 shares of company stock worth $139,215,946. 10.80% of the stock is currently owned by company insiders.

Roivant Sciences Stock Down 0.9%

Shares of ROIV stock opened at $27.52 on Thursday. The firm has a market cap of $19.70 billion, a price-to-earnings ratio of -23.52 and a beta of 1.20. Roivant Sciences Ltd. has a 52-week low of $10.58 and a 52-week high of $30.33. The company’s 50 day moving average is $28.28 and its 200 day moving average is $23.87.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.